Information de reference pour ce titreAccession Number: | 00006982-200710000-00001.
|
Author: | WONG, ROBERT W. MD; RICHA, D CHIMENE MD; HAHN, PAUL MD, PhD; GREEN, W RICHARD MD; DUNAIEF, JOSHUA L. MD, PhD
|
Institution: | From F. M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia; and The Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.
|
Title: | |
Source: | Retina. 27(8):997-1003, October 2007.
|
Abstract: | While it has been known for years that iron overload is associated with retinal degeneration in the context of ocular siderosis, intraocular hemorrhage, and the hereditary diseases aceruloplasminemia and pantothenate kinase associated neurodegeneration, recent evidence suggests that age-related macular degeneration (AMD) may also be exacerbated by retinal iron overload. In the retina, iron is necessary for normal cellular function. Iron overload, however, can cause retinal toxicity through the generation of oxygen free radicals. Histopathology of eyes with macular degeneration has shown elevated levels of iron in the retinal pigment epithelium, Bruch membrane, and within drusen, some of which was chelatable in vitro with deferoxamine. In this review, the authors summarize the evidence that iron overload may contribute to AMD pathogenesis. It is hoped that continued investigation of the role of iron and iron associated proteins in the retina will uncover clues to AMD pathogenesis and lead to new preventative or therapeutic options.
(C) The Ophthalmic Communications Society, Inc.
|
Author Keywords: | aceruloplasminemia; age-related macular degeneration; hemochromatosis; iron chelation; iron toxicity; oxidative stress; pantothenate kinase associated neurodegeneration.
|
References: | 1. Cibis PA, Yamashita T, Rodriguez F. Clinical aspects of ocular siderosis and hemosiderosis. AMA Arch Ophthalmol 1959;62:180-187.
2. Dunaief JL. Iron induced oxidative damage as a potential factor in age-related macular degeneration: the Cogan Lecture. Invest Ophthalmol Vis Sci 2006;47:4660-4664.
3. Shichi H. Microsomal electron transfer system of bovine retinal pigment epithelium. Exp Eye Res 1969;8:60-68.
4. Pedersen OO. An electron microscopic study of the permeability of intraocular blood vessels using lanthanum as a tracer in vivo. Exp Eye Res 1979;29:61-69.
5. Moiseyev G, Takahashi Y, Chen Y, et al. RPE65 is an iron(II)-dependent isomerohydrolase in the retinoid visual cycle. J Biol Chem 2006;281:2835-2840.
6. Hunt RC, Davis AA. Release of iron by human retinal pigment epithelial cells. J Cell Physiol 1992;152:102-110.
7. Yefimova MG, Jeanny JC, Guillonneau X, et al. Iron, ferritin, transferrin, and transferrin receptor in the adult rat retina. Invest Ophthalmol Vis Sci 2000;41:2343-2251.
8. Hahn P, Dentchev T, Qian Y, Rouault T, Harris ZL, Dunaief JL. Immunolocalization and regulation of iron handling proteins ferritin and ferroportin in the retina. Mol Vis 2004;10:598-607.
9. Yefimova MG, Jeanny JC, Keller N, et al. Impaired retinal iron homeostasis associated with defective phagocytosis in Royal College of Surgeons rats. Invest Ophthalmol Vis Sci 2002;43:537-545.
10. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci 1995;36:182-191.
11. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980;24:335-610.
12. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000;45:115-134.
13. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004;122:598-614.
14. AREDS. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins c and e, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol 2001;119:1417-1436.
15. Hahn P, Milam AH, Dunaief JL. Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch's membrane. Arch Ophthalmol 2003;121:1099-1105.
16. Russell SR, Mullins RF, Schneider BL, Hageman GS. Location, substructure, and composition of basal laminar drusen compared with drusen associated with aging and age-related macular degeneration. Am J Ophthalmol 2000;129:205-214.
17. Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci USA 2002;99:14682-14687.
18. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005;102:7227-7232.
19. Hahn P, Qian Y, Dentchev T, et al. Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proc Natl Acad Sci USA 2004;101:13850-13855.
20. Chowers I, Wong R, Dentchev T, et al. The iron carrier transferrin is upregulated in retinas from patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 2006;47:2135-2140.
21. Hahn P, Ying GS, Beard J, Dunaief JL. Iron levels in human retina: sex difference and increase with age. Neuroreport 2006;17:1803-1806.
22. Lee DW, Andersen JK, Kaur D. Iron dysregulation and neurodegeneration: the molecular connection. Mol Interv 2006;6:89-97.
23. Zacharski LR, Gerhard GS. Atherosclerosis: a manifestation of chronic iron toxicity? Vasc Med 2003;8:153-155.
24. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-389.
25. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005;308:421-424.
26. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005;308:419-421.
27. Magnusson KP, Duan S, Sigurdsson H, et al. CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med 2005;3:e5.
28. Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol 1982;94:762-773.
29. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 2006;38:458-462.
30. Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol Educ Program 2006:29-35.
31. Vogi W, Nolte R, Brunahl D. Binding of iron to the 5th component of human complement directs oxygen radical-mediated conversion to specific sites and causes nonenzymic activation. Complement Inflamm 1991;8:313-319.
32. Li ZL, Lam S, Tso MO. Desferrioxamine ameliorates retinal photic injury in albino rats. Curr Eye Res 1991;10:133-144.
33. Youssef TA, Trese MT, Hartzer M, et al. Deferoxamine reduced retinal toxicity from subretinal blood. Invest Ophthalmol 2002;43:E-abstract.
34. Trese MT. Visual results and prognostic factors for vision following surgery for stage V retinopathy of prematurity. Ophthalmology 1986;93:574-579.
35. Dunaief JL, Richa C, Franks EP, et al. Macular degeneration in a patient with aceruloplasminemia, a disease associated with retinal iron overload. Ophthalmology 2005;112:1062-1065.
36. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RT, Gitlin JD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci USA 1995;92:2539-2543.
37. Yamaguchi K, Takahashi S, Kawanami T, Kato T, Sasaki H. Retinal degeneration in hereditary ceruloplasmin deficiency. Ophthalmologica 1998;212:11-14.
38. Jeong SY, David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem 2003;278:27144-27148.
39. Tso MO, Zhang C, Abler AS, et al. Apoptosis leads to photoreceptor degeneration in inherited retinal dystrophy of RCS rats. Invest Ophthalmol Vis Sci 1994;35:2693-2699.
40. Bacon BR, Schilsky ML. New knowledge of genetic pathogenesis of hemochromatosis and Wilson's disease. Adv Intern Med 1999;44:91-116.
41. Feder JN, Penny DM, Irrinki A, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998;95:1472-1477.
42. Lebron JA, Bennett MJ, Vaughn DE, et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 1998;93:111-123.
43. Fleming RE, Sly WS. Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci USA 2001;98:8160-8162.
44. Roth AM, Foos RY. Ocular pathologic changes in primary hemochromatosis. Arch Ophthalmol 1972;87:507-514.
45. Hayflick SJ. Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name. Curr Opin Pediatr 2003;15:572-577.
46. Koeppen AH, Dickson AC. Iron in the Hallervorden-Spatz syndrome. Pediatr Neurol 2001;25:148-155.
47. Newell FW, Johnson RO 2nd, Huttenlocher PR. Pigmentary degeneration of the retina in the Hallervorden-Spatz syndrome. Am J Ophthalmol 1979;88:467-471.
48. Luckenbach MW, Green WR, Miller NR, Moser HW, Clark AW, Tennekoon G. Ocular clinicopathologic correlation of Hallervorden-Spatz syndrome with acanthocytosis and pigmentary retinopathy. Am J Ophthalmol 1983;95:369-382.
49. Zheng H, Weiner LM, Bar-Am O, et al. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem 2005;13:773-783.
50. Richardson DR. Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann N Y Acad Sci 2004;1012:326-341.
51. Arden GB, Wonke B, Kennedy C, Huehns ER. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol 1984;68:873-877.
52. Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 1983;2:181-184.
53. Lakhanpal V, Schocket SS, Jiji R. Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology 1984;91:443-451.
54. Leure-duPree AE, Connor MJ. The effect of deferoxamine, an iron chelator, on the morphology of the retina. Prog Clin Biol Res 1987;247:517-529.
55. Haimovici R, D'Amico DJ, Gragoudas ES, Sokol S. The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology 2002;109:164-171.
56. Kaur D, Yantiri F, Rajagopalan S, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003;37:899-909.
57. Waugh WH. Iron chelation by dibasic amino acid prevents glycoprotein insolubilities: a strategy to inhibit age-related macular degeneration? J Appl Res 2004;4:208-214.
58. Zacharski LR, Ornstein DL, Woloshin S, Schwartz LM. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J 2000;140:98-104.
59. Martin PM, Gnana-Prakasam JP, Roon P, Smith RG, Smith SB, Ganapathy V. Expression and polarized localization of the hemochromatosis gene product HFE in retinal pigment epithelium. Invest Ophthalmol Vis Sci 2006;47:4238-4244.
|
Language: | English.
|
Document Type: | Review Article.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0275-004X
|
NLM Journal Code: | r8r, 8309919
|
DOI Number: | https://dx.doi.org/10.1097/IAE.0...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|